Skip to main content
Erschienen in: International Journal of Hematology 5/2015

01.11.2015 | Original Article

Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells

verfasst von: Huibo Li, Xiaolin Kong, Gang Cui, Cuicui Ren, Shengjin Fan, Lili Sun, Yingjie Zhang, Rongyi Cao, Yinghua Li, Jin Zhou

Erschienen in: International Journal of Hematology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

The aim of the present study was to investigate the effects of rapamycin and its underlying mechanisms on acute lymphoblastic leukemia (ALL) cells. We found that the p14, p15, and p57 genes were not expressed in ALL cell lines (Molt-4 and Nalm-6) and adult ALL patients, whereas mTOR, 4E-BP1, and p70S6K were highly expressed. In Molt-4 and Nalm-6 cells exposed to rapamycin, cell viability decreased and the cell cycle was arrested at the G1/S phase. Rapamycin restored p14, p15, and p57 gene expression through demethylation of the promoters of these genes. As expected, rapamycin also increased p14 and p15 protein expression in both Molt-4 and Nalm-6 cells, as well as p57 protein expression in Nalm-6 cells. Rapamycin additionally decreased mTOR and p70S6K mRNA levels, as well as p70S6K and p-p70S6K protein levels. However, depletion of mTOR by siRNA did not alter the expression and promoter methylation states of p14, p15, and p57. These results indicate that the inhibitory effect of rapamycin may be due mainly to increased p14, p15, and p57 expression via promoter demethylation and decreased mTOR and p70S6K expression in ALL cell lines. These results suggest a potential role for rapamycin in the treatment of adult ALL.
Literatur
1.
Zurück zum Zitat Kantarjian H, Thomas D, O’Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788–801.CrossRefPubMed Kantarjian H, Thomas D, O’Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788–801.CrossRefPubMed
2.
Zurück zum Zitat Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15:163–205.CrossRefPubMed Garcia-Manero G, Thomas DA. Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15:163–205.CrossRefPubMed
3.
Zurück zum Zitat Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–84.CrossRefPubMed Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–84.CrossRefPubMed
4.
Zurück zum Zitat Li X, Yang Q, Yu H, Wu L, Zhao Y, Zhang C, et al. LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget. 2014;5:788–801.PubMedCentralCrossRefPubMed Li X, Yang Q, Yu H, Wu L, Zhao Y, Zhang C, et al. LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget. 2014;5:788–801.PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Kelly KR, Rowe JH, Padmanabhan S, Nawrocki ST, Carew JS. Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol. 2011;6:53–61.CrossRefPubMed Kelly KR, Rowe JH, Padmanabhan S, Nawrocki ST, Carew JS. Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol. 2011;6:53–61.CrossRefPubMed
7.
Zurück zum Zitat Herbert TP, Tee AR, Proud CG. The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J Biol Chem. 2002;277:11591–6.CrossRefPubMed Herbert TP, Tee AR, Proud CG. The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E-BP1 at multiple sites. J Biol Chem. 2002;277:11591–6.CrossRefPubMed
8.
Zurück zum Zitat Bahrami BF, Ataie-Kachoie P, Pourgholami MH, Morris DL. p70 ribosomal protein S6 kinase (Rps6kb1): an update. J Clin Pathol. 2014;67:1019–25.CrossRef Bahrami BF, Ataie-Kachoie P, Pourgholami MH, Morris DL. p70 ribosomal protein S6 kinase (Rps6kb1): an update. J Clin Pathol. 2014;67:1019–25.CrossRef
10.
Zurück zum Zitat García-Morales P, Hernando E, Carrasco-García E, Menéndez-Gutierrez MP, Saceda M, Martínez-Lacaci I. Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells. Mol Cancer Ther. 2006;5:2172–81.CrossRefPubMed García-Morales P, Hernando E, Carrasco-García E, Menéndez-Gutierrez MP, Saceda M, Martínez-Lacaci I. Cyclin D3 is down-regulated by rapamycin in HER-2-overexpressing breast cancer cells. Mol Cancer Ther. 2006;5:2172–81.CrossRefPubMed
11.
Zurück zum Zitat Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood. 2003;101:278–85.CrossRefPubMed Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood. 2003;101:278–85.CrossRefPubMed
12.
Zurück zum Zitat Williams RT, Sherr CJ. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and bcr-abl-induced leukemias. Cold Spring Harb Symp Quant Biol. 2008;73:461–7.CrossRefPubMed Williams RT, Sherr CJ. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and bcr-abl-induced leukemias. Cold Spring Harb Symp Quant Biol. 2008;73:461–7.CrossRefPubMed
13.
Zurück zum Zitat Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17:5001–14.PubMedCentralCrossRefPubMed Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17:5001–14.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Wolff L, Bies J. p15Ink4b functions in determining hematopoietic cell fates: implications for its role as a tumor suppressor. Blood Cells Mol Dis. 2013;50:227–31.CrossRefPubMed Wolff L, Bies J. p15Ink4b functions in determining hematopoietic cell fates: implications for its role as a tumor suppressor. Blood Cells Mol Dis. 2013;50:227–31.CrossRefPubMed
15.
Zurück zum Zitat Borriello A, Caldarelli I, Bencivenga D, Criscuolo M, Cucciolla V, Tramontano A, et al. p57(Kip2) and cancer: time for a critical appraisal. Mol Cancer Res. 2011;9:1269–84.CrossRefPubMed Borriello A, Caldarelli I, Bencivenga D, Criscuolo M, Cucciolla V, Tramontano A, et al. p57(Kip2) and cancer: time for a critical appraisal. Mol Cancer Res. 2011;9:1269–84.CrossRefPubMed
16.
Zurück zum Zitat Paul E, Paul E, Uggla B, Deneberg S, Bengtzen S, Hermansson M, et al. Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival. Leuk Lymphoma. 2009;50:1512–8.CrossRefPubMed Paul E, Paul E, Uggla B, Deneberg S, Bengtzen S, Hermansson M, et al. Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival. Leuk Lymphoma. 2009;50:1512–8.CrossRefPubMed
17.
Zurück zum Zitat Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood. 2004;104:2492–8.CrossRefPubMed Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood. 2004;104:2492–8.CrossRefPubMed
18.
Zurück zum Zitat Bueso-Ramos C, Xu Y, McDonnell TJ, Brisbay S, Pierce S, Kantarjian H, et al. Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J Clin Oncol. 2005;23:3932–9.CrossRefPubMed Bueso-Ramos C, Xu Y, McDonnell TJ, Brisbay S, Pierce S, Kantarjian H, et al. Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J Clin Oncol. 2005;23:3932–9.CrossRefPubMed
19.
Zurück zum Zitat Wong IH, Ng MH, Huang DP, Lee JC. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood. 2000;95:1942–9.PubMed Wong IH, Ng MH, Huang DP, Lee JC. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood. 2000;95:1942–9.PubMed
20.
Zurück zum Zitat Li Y, Nagai H, Ohno T, Yuge M, Hatano S, Ito E, et al. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood. 2002;100:2572–7.CrossRefPubMed Li Y, Nagai H, Ohno T, Yuge M, Hatano S, Ito E, et al. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood. 2002;100:2572–7.CrossRefPubMed
21.
Zurück zum Zitat Kohno T, Yamada Y, Tawara M, Takasaki Y, Kamihira S, Tomonaga M, et al. Inactivation of p14ARF as a key event for the progression of adult T cell leukemia/lymphoma. Leuk Res. 2007;31:1625–32.CrossRefPubMed Kohno T, Yamada Y, Tawara M, Takasaki Y, Kamihira S, Tomonaga M, et al. Inactivation of p14ARF as a key event for the progression of adult T cell leukemia/lymphoma. Leuk Res. 2007;31:1625–32.CrossRefPubMed
22.
Zurück zum Zitat Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMed Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMed
24.
Zurück zum Zitat Petroulakis E, Parsyan A, Dowling RJ, LeBacquer O, Martineau Y, Bidinosti M, et al. p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell. 2009;16:439–46.CrossRefPubMed Petroulakis E, Parsyan A, Dowling RJ, LeBacquer O, Martineau Y, Bidinosti M, et al. p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell. 2009;16:439–46.CrossRefPubMed
25.
Zurück zum Zitat Kwon HK, Bae GU, Yoon JW, Kim YK, Lee HY, Lee HW, et al. Constitutive activation of p70S6K in cancer cells. Arch Pharm Res. 2002;25:685–90.CrossRefPubMed Kwon HK, Bae GU, Yoon JW, Kim YK, Lee HY, Lee HW, et al. Constitutive activation of p70S6K in cancer cells. Arch Pharm Res. 2002;25:685–90.CrossRefPubMed
26.
Zurück zum Zitat Vispé S, Deroide A, Davoine E, Desjobert C, Lestienne F, Fournier L, et al. Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2′-deoxycytidine in human leukemic KG1 cells. Oncotarget. 2015;6:15265–82.PubMedCentralCrossRefPubMed Vispé S, Deroide A, Davoine E, Desjobert C, Lestienne F, Fournier L, et al. Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2′-deoxycytidine in human leukemic KG1 cells. Oncotarget. 2015;6:15265–82.PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Tasian SK, Teachey DT, Rheingold SR. Targeting the PI3K/mTOR pathway in pediatric hematologic malignancies. Front Oncol. 2014;4:108.PubMedCentralPubMed Tasian SK, Teachey DT, Rheingold SR. Targeting the PI3K/mTOR pathway in pediatric hematologic malignancies. Front Oncol. 2014;4:108.PubMedCentralPubMed
28.
Zurück zum Zitat Márk Á, Hajdu M, Váradi Z, Sticz TB, Nagy N, Csomor J, et al. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease–—a combined tissue microarray, in vitro and in vivo study. BMC Cancer. 2013;13:250.PubMedCentralCrossRefPubMed Márk Á, Hajdu M, Váradi Z, Sticz TB, Nagy N, Csomor J, et al. Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease–—a combined tissue microarray, in vitro and in vivo study. BMC Cancer. 2013;13:250.PubMedCentralCrossRefPubMed
29.
Zurück zum Zitat Tian F, Dong L, Zhou Y, Shao Y, Li W, Zhang H, et al. Rapamycin-induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathways. Int J Mol Sci. 2014;15:13833–48.PubMedCentralCrossRefPubMed Tian F, Dong L, Zhou Y, Shao Y, Li W, Zhang H, et al. Rapamycin-induced apoptosis in HGF-stimulated lens epithelial cells by AKT/mTOR, ERK and JAK2/STAT3 pathways. Int J Mol Sci. 2014;15:13833–48.PubMedCentralCrossRefPubMed
30.
Zurück zum Zitat Li J, Xue L, Hao H, Li R, Luo J. Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway. Tumour Biol. 2014;35:6467–74.CrossRefPubMed Li J, Xue L, Hao H, Li R, Luo J. Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway. Tumour Biol. 2014;35:6467–74.CrossRefPubMed
31.
Zurück zum Zitat Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837–41.PubMed Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837–41.PubMed
32.
Zurück zum Zitat Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood. 2003;101:4131–6.CrossRefPubMed Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood. 2003;101:4131–6.CrossRefPubMed
33.
Zurück zum Zitat Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian HM, Issa JP. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res. 2002;8:1897–903.PubMed Garcia-Manero G, Bueso-Ramos C, Daniel J, Williamson J, Kantarjian HM, Issa JP. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res. 2002;8:1897–903.PubMed
34.
Zurück zum Zitat Hagiwara K, Li Y, Kinoshita T, Kunishma S, Ohashi H, Hotta T, et al. Aberrant DNA methylation of the p57KIP2 gene is a sensitive biomarker for detecting minimal residual disease in diffuse large B cell lymphoma. Leuk Res. 2010;34:50–4.CrossRefPubMed Hagiwara K, Li Y, Kinoshita T, Kunishma S, Ohashi H, Hotta T, et al. Aberrant DNA methylation of the p57KIP2 gene is a sensitive biomarker for detecting minimal residual disease in diffuse large B cell lymphoma. Leuk Res. 2010;34:50–4.CrossRefPubMed
35.
Zurück zum Zitat Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, et al. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood. 2009;113:1892–8.PubMedCentralCrossRefPubMed Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, et al. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood. 2009;113:1892–8.PubMedCentralCrossRefPubMed
36.
Zurück zum Zitat Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P, et al. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood. 2012;119:5201–10.PubMedCentralCrossRefPubMed Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P, et al. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood. 2012;119:5201–10.PubMedCentralCrossRefPubMed
37.
Zurück zum Zitat Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR, et al. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2014;89:889–95.PubMedCentralCrossRefPubMed Burke MJ, Lamba JK, Pounds S, Cao X, Ghodke-Puranik Y, Lindgren BR, et al. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2014;89:889–95.PubMedCentralCrossRefPubMed
38.
Zurück zum Zitat Tomasoni R, Basso V, Pilipow K, Sitia G, Saccani S, Agresti A, et al. Rapamycin-sensitive signals control TCR/CD28-driven Ifng, Il4 and Foxp3 transcription and promoter region methylation. Eur J Immunol. 2011;41:2086–96.CrossRefPubMed Tomasoni R, Basso V, Pilipow K, Sitia G, Saccani S, Agresti A, et al. Rapamycin-sensitive signals control TCR/CD28-driven Ifng, Il4 and Foxp3 transcription and promoter region methylation. Eur J Immunol. 2011;41:2086–96.CrossRefPubMed
39.
Zurück zum Zitat Sun D, Toan X, Zhang Y, Chen Y, Lu R, Wang X, et al. Mammalian target of rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines. Sci China C Life Sci. 2008;51:640–7.CrossRefPubMed Sun D, Toan X, Zhang Y, Chen Y, Lu R, Wang X, et al. Mammalian target of rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines. Sci China C Life Sci. 2008;51:640–7.CrossRefPubMed
40.
Zurück zum Zitat Zheng J, Hudder A, Zukowski K, Novak RF. Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells. Cancer Lett. 2010;296:74–87.PubMedCentralCrossRefPubMed Zheng J, Hudder A, Zukowski K, Novak RF. Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells. Cancer Lett. 2010;296:74–87.PubMedCentralCrossRefPubMed
41.
Zurück zum Zitat Daniel C, Wennhold K, Kim HJ, von Boehmer H. Enhancement of antigen-specific Treg vaccination in vivo. Proc Natl Acad Sci USA. 2010;107:16246–51.PubMedCentralCrossRefPubMed Daniel C, Wennhold K, Kim HJ, von Boehmer H. Enhancement of antigen-specific Treg vaccination in vivo. Proc Natl Acad Sci USA. 2010;107:16246–51.PubMedCentralCrossRefPubMed
42.
Zurück zum Zitat Cheng ZY, Guo XL, Yang XY, Niu ZY, Li SH, Wang SY, et al. PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway. J Exp Clin Cancer Res. 2008;27:87.PubMedCentralCrossRefPubMed Cheng ZY, Guo XL, Yang XY, Niu ZY, Li SH, Wang SY, et al. PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway. J Exp Clin Cancer Res. 2008;27:87.PubMedCentralCrossRefPubMed
43.
Zurück zum Zitat Chiarini F, Falà F, Tazzari PL, Ricci F, Astolfi A, Pession A, et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res. 2009;69:3520–8.CrossRefPubMed Chiarini F, Falà F, Tazzari PL, Ricci F, Astolfi A, Pession A, et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res. 2009;69:3520–8.CrossRefPubMed
44.
Zurück zum Zitat Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006;66:6589–97.CrossRefPubMed Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006;66:6589–97.CrossRefPubMed
45.
Zurück zum Zitat Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol. 2006;169:2171–80.PubMedCentralCrossRefPubMed Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol. 2006;169:2171–80.PubMedCentralCrossRefPubMed
46.
Zurück zum Zitat Gu L, Zhou C, Liu H, Gao J, Li Q, Mu D, et al. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. J Exp Clin Cancer Res. 2010;29:150.PubMedCentralCrossRefPubMed Gu L, Zhou C, Liu H, Gao J, Li Q, Mu D, et al. Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. J Exp Clin Cancer Res. 2010;29:150.PubMedCentralCrossRefPubMed
47.
Zurück zum Zitat Brown VI, Fang J, Alcorn K, Barr R, Kim JM, Wasserman R, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA. 2003;100:15113–8.PubMedCentralCrossRefPubMed Brown VI, Fang J, Alcorn K, Barr R, Kim JM, Wasserman R, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA. 2003;100:15113–8.PubMedCentralCrossRefPubMed
48.
Zurück zum Zitat Wang Z, Xu F, Yuan N, Niu Y, Lin W, Cao Y, et al. Rapamycin inhibits pre-B acute lymphoblastic leukemia cells by downregulating DNA and RNA polymerases. Leuk Res. 2014;38:940–7.CrossRefPubMed Wang Z, Xu F, Yuan N, Niu Y, Lin W, Cao Y, et al. Rapamycin inhibits pre-B acute lymphoblastic leukemia cells by downregulating DNA and RNA polymerases. Leuk Res. 2014;38:940–7.CrossRefPubMed
49.
Zurück zum Zitat Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, et al. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J. 2005;19:960–2.PubMed Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, et al. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J. 2005;19:960–2.PubMed
50.
Zurück zum Zitat Yang X, He G, Gong Y, Zheng B, Shi F, Shi R, et al. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells. Eur J Haematol. 2014;92:111–20.CrossRefPubMed Yang X, He G, Gong Y, Zheng B, Shi F, Shi R, et al. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells. Eur J Haematol. 2014;92:111–20.CrossRefPubMed
51.
Zurück zum Zitat Altman JK, Platanias LC. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol. 2008;15:88–94.CrossRefPubMed Altman JK, Platanias LC. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol. 2008;15:88–94.CrossRefPubMed
Metadaten
Titel
Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells
verfasst von
Huibo Li
Xiaolin Kong
Gang Cui
Cuicui Ren
Shengjin Fan
Lili Sun
Yingjie Zhang
Rongyi Cao
Yinghua Li
Jin Zhou
Publikationsdatum
01.11.2015
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 5/2015
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1858-1

Weitere Artikel der Ausgabe 5/2015

International Journal of Hematology 5/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.